Revolutionizing Neuroscience: Integrating Stem Cells, Organoids, and Neurons in Hybrid Brain Studies
Hybrid brains will allow researchers to better understand how brain cells get sick or die and better understand the rules of repairing and replacing parts of the brain (Source: Disabled World)
Source: Disabled World - April 25, 2024 Category: Disability Tags: Organoids Source Type: news
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
THURSDAY, April 25, 2024 -- For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by haploidentical hematopoietic stem-cell transplantation (HSCT) is safe... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2024 Category: Pharmaceuticals Source Type: news
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
(MedPage Today) -- A strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without graft-versus-host disease (GVHD) prophylaxis, is a feasible approach for patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 24, 2024 Category: Hematology Source Type: news
Parental Fury After Stem Cell Bank Ruins Thousands of Samples in Singapore
(Source: Reuters: Health)
Source: Reuters: Health - April 21, 2024 Category: Consumer Health News Source Type: news
Beauty-Stem Biomedical Celebrates Grand Opening in Arcadia, Los Angeles
Beauty-Stem Biomedical, a cutting-edge stem cell supplement company, marked a momentous occasion with its grand opening in the vibrant city of Arcadia. The event was a resounding success, drawing health enthusiasts, researchers, and industry leaders from far and wide. LOS ANGELES, April... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 18, 2024 Category: Pharmaceuticals Source Type: news
Met investigates 'stem-cell autism cure' claim
The local council says it is aware of concerns over "experimental procedures" on autistic children. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 17, 2024 Category: Consumer Health News Source Type: news
Roche ’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III...
Source: Roche Media News - April 17, 2024 Category: Pharmaceuticals Source Type: news
EGFR-dependent endocytosis of Wnt9a and Fzd9b promotes β-catenin signaling during hematopoietic stem cell development in zebrafish | Science Signaling
Fzd9b signaling induced by the ligand Wnt9a requires their endocytosis in an EGFR-dependent manner. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 16, 2024 Category: Science Source Type: news
Augustinus Bader: the making of a cult skincare phenomenon
Professor Bader and CEO Charles Rosier on stem cell technology, skincare and the science behind their best-selling brand (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 16, 2024 Category: Pharmaceuticals Source Type: news
Rejuvenating the immune system by depleting certain stem cells
Researchers found that depleting certain stem cells improved the immune systems of aged mice. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - April 16, 2024 Category: Consumer Health News Source Type: news
Advance in immune cell screening uncovers receptors that target prostate cancer
This study validated the ability for nanovials to find T cells, and their receptors, that react to viruses.A second experiment with a different patient applied the technology to a much more challenging problem: rare prostate cancer targets the scientists had identified in previous studies. Importantly, those molecular targets acted to both capture the T cells and cause them to secrete certain molecules that kill target cells. In other experiments, the nanovials also had molecules allowing each to capture more than one type of immune-activating secretion.CNSI at UCLAA closer look at UCLA-developed nanovials, which are hydro...
Source: UCLA Newsroom: Health Sciences - April 15, 2024 Category: Universities & Medical Training Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Investor Update - April 15, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Media News - April 15, 2024 Category: Pharmaceuticals Source Type: news
The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage and MS
Stem cell transplants - in which 'blank, shape-shifting' cells are implanted to miraculously repair injured tissue - are the new frontier of regenerative medicine. (Source: the Mail online | Health)
Source: the Mail online | Health - April 13, 2024 Category: Consumer Health News Source Type: news
Low Intracellular Iron Levels May Keep Blood Stem Cells Young
Removing excess iron from aging mouse blood-forming cells enhances their regenerative capacity. (Source: The Scientist)
Source: The Scientist - April 8, 2024 Category: Science Tags: News News & Opinion Source Type: news
